Loading...
Temsirolimus and Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma: a multi-center Phase 2 Study
BACKGROUND: Temsirolimus is an mTOR inhibitor with single-agent antitumor activity in patients with mantle cell lymphoma (MCL). We therefore tested the efficacy and toxicity of temsirolimus in combination with rituximab in patients with relapsed or refractory MCL. METHODS: Patients received temsirol...
Na minha lista:
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
2011
|
Fag: | |
Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3106222/ https://ncbi.nlm.nih.gov/pubmed/21440503 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(11)70062-6 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|